BCMA-targeted immunotherapy for multiple myeloma

Journal of Hematology & Oncology

Bo Yu¹  Delong Liu²  Tianbo Jiang² 

[1] Department of Medicine, Lincoln Medical Center, Bronx, NY, USA;Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA;

关键词: B cell maturation antigen;    BCMA;    Belantamab mafodotin;    CAR-T;    Antibody-drug conjugate;    Bispecific T cell engager;   

DOI  :  10.1186/s13045-020-00962-7

来源: Springer

【 摘 要 】

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.

【 授权许可】

CC BY